Hoth Therapeutics Inc HOTH.OQ HOTH.O is expected to show no change in quarterly revenue when it reports results on August 7 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Hoth Therapeutics Inc is for a loss of 14 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Hoth Therapeutics Inc is $4.50, about 69.3% above its last closing price of $1.38
This summary was machine generated August 5 at 22:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)